Home › Biomarkers › MET
MET testing: what it means for you
Waiting on test results can feel like one more hard thing, for you and the people who love you. Here's what the MET test looks for and how it can help your care team pick the treatment most likely to work for you.
ℹ️ General information to help you and your loved ones talk with your care team, not medical advice. Read our disclaimer.
Matters most in: Lung cancer
The quick guide
What the test looks for: Changes in the MET gene in lung cancer, mainly 'exon 14 skipping' mutations (about 3–4% of non-small cell lung cancers) and extra copies (amplification), plus high MET protein.
Why it matters
MET exon 14 skipping can be treated with MET-targeted pills. MET changes can also be how EGFR-positive cancer stops responding to treatment.
Treatments it can point to
- MET pills such as capmatinib or tepotinib
- For high MET protein, the antibody-drug conjugate telisotuzumab vedotin
Only your care team can say which treatment fits you. Drug approvals depend on cancer type, stage and prior treatment.
Tissue vs. blood testing
Tissue (an RNA-based panel finds exon 14 skipping best) or blood.
Most tests use a piece of tumor tissue from a biopsy or surgery. Some can also use a blood sample (a 'liquid biopsy') that looks for tumor DNA floating in the blood. Blood tests are easier and faster, but they can miss a change that a tissue test would find, so a negative blood test is often followed by a tissue test.
❓ Questions you and your loved ones can ask
- Did my panel include RNA testing for MET exon 14?
- When will my results be back, and will treatment wait for them?
- Will my insurance cover this test?
Written by the Cancer Side Effects Guide team from FDA labels and leading cancer centers. Not medical advice. · Last updated: October 15, 2026 · How we write
Sources
- ACS: Targeted Drug Therapy for Non-small Cell Lung Cancer
- Memorial Sloan Kettering: Lung Cancer Treatment
- NCI: Biomarker Testing for Cancer Treatment
- FDA: List of Cleared or Approved Companion Diagnostic Devices
- NCCN Guidelines for Patients: Early and Locally Advanced Non-Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer, 2026
- NCCN Guidelines for Patients: Small Cell Lung Cancer, 2026